Firms marketing OTC drugs in the US, for the first time since the COVID-19 pandemic began, might look ahead to welcome changes rather than over their shoulders for the next unexpected headwind or hurdle when they report their results for the January-March period.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?